1. In Vivo
  2. >>Innovation

Big Pharma's Practice-Changing Data Dominates At ESMO

 
• By Kevin Grogan

Unseasonal showers hit Madrid during the European Society for Medical Oncology congress where most of the major data readouts came from the biggest players in the sector rather than ambitious biotechs. Here, In Vivo looks at three must-see presentations from the prestigious meeting.  

Cancer cell

It is always a good sign when your presentation is interrupted by a standing ovation. This was the fate of Tom Powles, director of Barts Cancer Centre in London, at an ESMO presidential symposium where he gave the detailed results of the Phase III EV-302/KEYNOTE-A39 trial looking at the combination of Seagen Inc. and Astellas Pharma, Inc.'s antibody-drug conjugate Padcev (enfortumab vedotin) and Merck & Co., Inc.'s checkpoint inhibitor Keytruda (pembrolizumab), as front-line therapy in patients with locally advanced or metastatic urothelial carcinoma (UC), which covers almost all bladder cancers.

The combo was the first regimen containing an ADC and an anti-PD-1/L1 agent to gain a US green light in...

Welcome to In Vivo

Create an account to read this article

Already a subscriber?

More from Innovation

Trojan Bio Eyes Perfect Rainbow Shot With Immune System Cancer Innovations

 
• By Ashley Yeo

Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By David Wild

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.